Quantcast

Latest Protease inhibitor Stories

2008-11-04 03:00:16

Anadys Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of the leading non-nucleoside polymerase inhibitors currently in development for the treatment of hepatitis C virus. In the Phase I study in healthy volunteers, ANA598 was administered as capsules at single oral doses of 400mg, 800mg, 1400mg, 2000mg and 3000mg. In addition, a...

2008-11-03 09:00:40

Tibotec, a pharmaceutical R&D company, has presented positive interim data from Phase IIa hepatitis study which demonstrated the antiviral activity of TMC435, an investigational protease inhibitor being developed by the company for the treatment of chronic hepatitis C virus infection. In interim findings from the first 28 days of treatment for the first cohort of 50 treatment naive hepatitis C virus plus (HCV+), genotype 1, patients (once daily dose of 25mg or 75mg TMC435 versus...

2008-11-01 12:00:05

SAN FRANCISCO, Nov. 1 /PRNewswire/ -- New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Tibotec will present findings from three TMC435 studies, including a late-breaker poster on the proof-of-principle phase IIa trial, OPERA-1 (TMC435-C201), at the American Association for the Study of Liver Disease's (AASLD) Liver Meeting 2008 in San Francisco. The...

2008-10-30 03:00:27

Phenomix, a biopharmaceutical company, has begun administering subjects in a Phase Ia clinical trial of PHX1766, the company's internally discovered, orally available NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus infection. The study is being conducted at clinical sites in the Netherlands and will enroll approximately 24 healthy subjects and six hepatitis C virus (HCV) infected patients. In this double-blind, randomized, placebo-controlled Phase Ia study,...

2008-10-28 12:00:39

Phenomix Corporation today announced it has begun administering subjects in a Phase 1a clinical trial of PHX1766, the company's internally discovered, orally available NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. The study is being conducted at clinical sites in the Netherlands and will enroll approximately 24 healthy subjects and six HCV infected patients. In this double-blind, randomized, placebo-controlled Phase 1a study, subjects will be...

2008-10-26 12:00:11

WASHINGTON, Oct. 26 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today reported a data analysis showing that vicriviroc, its investigational CCR5 receptor antagonist, demonstrated sustained viral suppression and increased CD4 cell counts and was well tolerated through up to four years of therapy in treatment-experienced HIV-infected patients. Vicriviroc was administered once-daily as a single tablet in combination with an optimized antiretroviral regimen containing a...

2008-10-26 12:00:10

In a new Phase III study that compared Merck & Co., Inc.'s HIV integrase inhibitor ISENTRESS(R) (raltegravir) to efavirenz (one of the leading antiretrovirals prescribed for previously untreated (treatment-naive) HIV-infected patients), ISENTRESS reduced HIV viral load to undetectable levels (less than 50 copies/mL) in 86 percent of patients compared to 82 percent of patients treated with efavirenz in previously untreated HIV patients at Week 48. Both medicines were taken in combination...

2008-09-24 09:00:13

BRISBANE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227) accepted for presentation at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, Oct. 31 - Nov. 4 in San Francisco), may now be viewed at http://www.aasld.org/. ITMN-191 is a hepatitis C virus (HCV) NS3 protease inhibitor, currently in a Phase 1b clinical trial in combination with Pegasys(R)...

2008-09-17 06:00:36

Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it has successfully completed dose escalation in the Phase 1 human clinical trial of Vivecon(TM), its HIV viral maturation inhibitor, in healthy volunteers. The trial demonstrated a favorable safety profile with Vivecon in 55 subjects enrolled across 9 cohorts. The Phase 1 trial was designed as a single ascending dose study to assess the safety, tolerability and pharmacokinetic parameters of the compound in healthy...

2008-09-10 18:00:34

ATTENTION BUSINESS/FINANCIAL/HEALTH EDITORS Ambrilia Biopharma Inc. (TSX: AMB) today announced that Dr. Philippe Calais, President and CEO, will present the Company and its projects at the Sachs Associates 8th Annual Biotech in Europe Investor Forum to be held in Zurich, September 23-24. This presentation will take place on Tuesday, September 23, Basel room (Swissotel), at 2:30 pm local time. ABOUT AMBRILIA BIOPHARMA Ambrilia Biopharma Inc. (TSX: AMB) is a biotechnology company focused...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.